|
gptkbp:instance_of
|
gptkb:DNA
|
|
gptkbp:associated_with
|
gptkb:chronic_myeloid_leukemia
|
|
gptkbp:clinical_trial
|
CML treatment
target for tyrosine kinase inhibitors
|
|
gptkbp:code
|
ABL proto-oncogene 1 protein
|
|
gptkbp:conducts_research_on
|
molecular biology
targeted therapy
|
|
gptkbp:discovered_by
|
gptkb:Dr._Janet_Rowley
|
|
gptkbp:genetic_studies
|
gptkb:Philadelphia_chromosome
cancer genetics
|
|
gptkbp:has_function
|
tyrosine kinase activity
|
|
gptkbp:has_role
|
cell proliferation
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ABL1
|
|
gptkbp:interacts_with
|
gptkb:BCR_gene
|
|
gptkbp:involved_in
|
signal transduction
|
|
gptkbp:is_associated_with
|
gptkb:Oncology
|
|
gptkbp:is_associated_with_clinical_outcome
|
treatment response
|
|
gptkbp:is_associated_with_genetic_alterations
|
chromosomal translocations
|
|
gptkbp:is_associated_with_mutation
|
T315 I mutation
|
|
gptkbp:is_associated_with_prognosis
|
chronic myeloid leukemia outcomes
|
|
gptkbp:is_associated_with_resistance
|
targeted therapies
|
|
gptkbp:is_expressed_in
|
hematopoietic cells
|
|
gptkbp:is_expressed_in_cancer
|
solid tumors
|
|
gptkbp:is_expressed_in_cell_lines
|
leukemia cell lines
|
|
gptkbp:is_expressed_in_models
|
animal models
|
|
gptkbp:is_expressed_in_tissues
|
bone marrow
|
|
gptkbp:is_expressed_in_tumors
|
hematologic malignancies
|
|
gptkbp:is_involved_in
|
cell differentiation
|
|
gptkbp:is_involved_in_cell_signaling
|
proliferation pathways
|
|
gptkbp:is_involved_in_clinical_research
|
CML therapies
|
|
gptkbp:is_involved_in_disease
|
myeloproliferative disorders
|
|
gptkbp:is_involved_in_pathophysiology
|
leukemogenesis
|
|
gptkbp:is_involved_in_signal_pathway
|
MAPK pathway
|
|
gptkbp:is_linked_to
|
imatinib resistance
|
|
gptkbp:is_linked_to_biomarker
|
response to therapy
|
|
gptkbp:is_linked_to_mutation
|
gptkb:BCR-ABL_fusion_protein
|
|
gptkbp:is_linked_to_therapy
|
combination therapy
|
|
gptkbp:is_part_of
|
cancer research
|
|
gptkbp:is_part_of_clinical_guidelines
|
CML management
|
|
gptkbp:is_part_of_therapeutic_strategy
|
precision medicine
|
|
gptkbp:is_recognized_as
|
1970s
|
|
gptkbp:is_regulated_by
|
growth factors
|
|
gptkbp:is_studied_for
|
drug resistance mechanisms
|
|
gptkbp:is_studied_for_impact_on
|
cell migration
|
|
gptkbp:is_studied_for_potential
|
therapeutic targets
|
|
gptkbp:is_studied_for_role_in
|
tumor progression
|
|
gptkbp:is_studied_in
|
oncology
|
|
gptkbp:is_targeted_at
|
novel therapeutic agents
|
|
gptkbp:is_targeted_by_drug
|
gptkb:nilotinib
|
|
gptkbp:is_targeted_by_inhibitor
|
bosutinib
|
|
gptkbp:is_targeted_by_new_drugs
|
gptkb:ponatinib
|
|
gptkbp:located_in
|
human chromosome 9
|
|
gptkbp:mechanism_of_action
|
cell survival
tyrosine kinase inhibitors
|
|
gptkbp:orthologs
|
gptkb:mouse
|
|
gptkbp:pathway
|
Ras signaling pathway
cell cycle regulation
|
|
gptkbp:research_areas
|
cancer genomics
|
|
gptkbp:bfsParent
|
gptkb:Philadelphia_chromosome
|
|
gptkbp:bfsLayer
|
5
|